Atlas Trials

Liquidia Technologies, Inc.

10 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Liquidia Technologies, Inc.

RecordFirmDate
A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks (NCT07748000)Liquidia Technologies, Inc.2026-10-26
A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag (NCT07759804)Liquidia Technologies, Inc.2026-09-01
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD (NCT07285655)Liquidia Technologies, Inc.2026-04-23
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH (NCT06129240)Liquidia Technologies, Inc.2023-12-28
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD (NCT04691154)Liquidia Technologies, Inc.2021-08-01
Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil (NCT03884465)Liquidia Technologies, Inc.2019-11-11
Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil (NCT03992755)Liquidia Technologies, Inc.2019-07-18
Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil (NCT03399604)Liquidia Technologies, Inc.2018-01-02

Track Liquidia Technologies, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.